Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio
Globus will buy all outstanding Nevro shares for $5.85 per share under the terms of the agreement, therefore reflecting a 27% premium over its 90-day volume-weighted average price and a 17% premium over its closing price on Feb.
Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an ...
With the addition of Nevro, Globus said it anticipates in annual net sales this year to total between $2.8 billion and $2.9 billion. Globus Medical’s financial adviser for the deal is Morgan ...
Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a ...
Zacks.com on MSN4d
Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
Hosted on MSN4d
Nevro upgraded to Neutral from Underweight at Piper SandlerPiper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company ...
Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition ...
Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback